ATG7 and in situ carcinoma: Serum creatinine and BUN were reduced from 1.9 and 158 mg/dl in the cisplatin group to 1.2 and 119 mg/dl in the cisplatin+TSA group, respectively (Fig. 9a, c: PT-Atg7 WT, CIS vs CIS+TSA).